Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) Director Carl Dambkowski sold 12,583 shares of Oruka Therapeutics stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $70.11, for a total value of $882,194.13. Following the sale, the director directly owned 38,743 shares of the company’s stock, valued at $2,716,271.73. This trade represents a 24.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Carl Dambkowski also recently made the following trade(s):
- On Thursday, June 11th, Carl Dambkowski sold 22,417 shares of Oruka Therapeutics stock. The shares were sold at an average price of $70.13, for a total value of $1,572,104.21.
- On Thursday, May 21st, Carl Dambkowski sold 105,000 shares of Oruka Therapeutics stock. The stock was sold at an average price of $58.97, for a total value of $6,191,850.00.
Oruka Therapeutics Price Performance
ORKA stock opened at $69.89 on Monday. The business has a 50 day moving average price of $63.40 and a 200 day moving average price of $44.04. The stock has a market cap of $4.22 billion, a price-to-earnings ratio of -36.03 and a beta of -0.25. Oruka Therapeutics, Inc. has a fifty-two week low of $10.77 and a fifty-two week high of $91.00.
Analyst Upgrades and Downgrades
ORKA has been the topic of a number of recent analyst reports. Stifel Nicolaus increased their target price on shares of Oruka Therapeutics from $47.00 to $72.00 and gave the company a “buy” rating in a research report on Friday, March 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Tuesday, April 21st. Wedbush set a $165.00 price objective on Oruka Therapeutics in a report on Monday, April 27th. Piper Sandler reiterated an “overweight” rating and set a $180.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, June 2nd. Finally, Guggenheim set a $200.00 target price on Oruka Therapeutics and gave the company a “buy” rating in a report on Monday, April 27th. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Oruka Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $131.30.
Check Out Our Latest Stock Report on ORKA
Institutional Trading of Oruka Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the business. Legal & General Group Plc purchased a new position in Oruka Therapeutics during the 2nd quarter worth $28,000. BNP Paribas Financial Markets raised its holdings in shares of Oruka Therapeutics by 464.0% in the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock valued at $31,000 after buying an additional 2,306 shares during the last quarter. Royal Bank of Canada boosted its stake in shares of Oruka Therapeutics by 47.2% during the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after buying an additional 365 shares during the period. Los Angeles Capital Management LLC acquired a new stake in shares of Oruka Therapeutics during the fourth quarter worth about $37,000. Finally, PNC Financial Services Group Inc. purchased a new position in shares of Oruka Therapeutics during the third quarter worth about $39,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.
About Oruka Therapeutics
Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”
The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.
Featured Stories
- Five stocks we like better than Oruka Therapeutics
- 3 ETFs Giving Ready-Made Access to the Discounted International Small-Cap Space
- What to Expect From Q2 Earnings as Tech Strength Broadens
- Viasat’s Orbiting Profits: Space Force Jackpot?
- Robinhood Wants a Bigger Role in IPOs—Here’s Why It Matters
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
